These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32460588)

  • 1. The Repeatability of Inspiration Performance Through Different Inhalers in Patients with Chronic Obstructive Pulmonary Disease and Control Volunteers.
    Erdelyi T; Lazar Z; Odler B; Tamasi L; Müller V
    J Aerosol Med Pulm Drug Deliv; 2020 Oct; 33(5):271-281. PubMed ID: 32460588
    [No Abstract]   [Full Text] [Related]  

  • 2. Modeling of pulmonary deposition of agents of open and fixed dose triple combination therapies through two different low-resistance inhalers in COPD: a pilot study.
    Erdelyi T; Lazar Z; Farkas Á; Furi P; Nagy A; Müller V
    Front Med (Lausanne); 2023; 10():1065072. PubMed ID: 37215734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
    Altman P; Wehbe L; Dederichs J; Guerin T; Ament B; Moronta MC; Pino AV; Goyal P
    BMC Pulm Med; 2018 Jun; 18(1):100. PubMed ID: 29898702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey.
    Price D; Keininger DL; Viswanad B; Gasser M; Walda S; Gutzwiller FS
    Int J Chron Obstruct Pulmon Dis; 2018; 13():695-702. PubMed ID: 29520137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
    Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
    Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of relationships between native and inhalation device specific spirometric parameters as a step towards patient tailored inhalation device selection.
    Farkas Á; Szipőcs A; Horváth A; Horváth I; Gálffy G; Varga J; Galambos K; Kugler S; Nagy A; Szalai Z
    Respir Med; 2019; 154():133-140. PubMed ID: 31252206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
    Brand P; Hederer B; Austen G; Dewberry H; Meyer T
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):763-70. PubMed ID: 19281091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
    Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
    Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices.
    Ram FS; Carvallho CR; White J
    Int J Chron Obstruct Pulmon Dis; 2011; 6():129-39. PubMed ID: 21468167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferences and Inhalation Techniques for Inhaler Devices Used by Patients with Chronic Obstructive Pulmonary Disease.
    Bournival R; Coutu R; Goettel N; Yang CD; Cantin-Lafleur A; Lemieux C; Lévesque AM; Patenaude-Monette JF; Roy FO; Blais L; Arbour F; Fillion A; Beauchesne MF
    J Aerosol Med Pulm Drug Deliv; 2018 Aug; 31(4):237-247. PubMed ID: 29206566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation.
    Price DB; Yang S; Ming SWY; Hardjojo A; Cabrera C; Papaioannou AI; Loukides S; Kritikos V; Bosnic-Anticevich SZ; Carter V; Dorinsky PM
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3937-3946. PubMed ID: 30587952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD.
    Ghosh S; Pleasants RA; Ohar JA; Donohue JF; Drummond MB
    Int J Chron Obstruct Pulmon Dis; 2019; 14():585-595. PubMed ID: 30880948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal Peak Inspiratory Flow in Patients Hospitalized for COPD Exacerbation: Prevalence and Predictive Factors.
    González-Montaos A; Pazos-Area L; Represas-Represas C; Ramos-Hernández C; Lojo-Rodríguez I; Priegue-Carrera A; Aballe-Santos L; Fernández-Villar A
    J Aerosol Med Pulm Drug Deliv; 2024 Oct; 37(5):225-231. PubMed ID: 39388689
    [No Abstract]   [Full Text] [Related]  

  • 15. Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial.
    Gregoriano C; Dieterle T; Breitenstein AL; Dürr S; Baum A; Maier S; Arnet I; Hersberger KE; Leuppi JD
    Respir Res; 2018 Dec; 19(1):237. PubMed ID: 30509268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The variability of peak inspiratory flow (PIF) on valves imitating dry powder inhalers resistance during asthma and COPD exacerbations].
    Grabowski M; Barg W; Chmielowicz B; Kopeć A; Panaszek B
    Pneumonol Alergol Pol; 2007; 75(4):324-30. PubMed ID: 18080981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.
    Malmberg LP; Rytilä P; Happonen P; Haahtela T
    Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():257-62. PubMed ID: 20714380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Peak Inspiratory Flow After Acute Bronchodilation: An Observational Study of Patients with Stable Chronic Obstructive Pulmonary Disease.
    Pleasants RA; Shaikh A; Henderson AG; Bayer V; Drummond MB
    J Aerosol Med Pulm Drug Deliv; 2024 Aug; 37(4):171-179. PubMed ID: 38814000
    [No Abstract]   [Full Text] [Related]  

  • 19. Inspiratory flow rates at different levels of resistance in elderly COPD patients.
    Janssens W; VandenBrande P; Hardeman E; De Langhe E; Philps T; Troosters T; Decramer M
    Eur Respir J; 2008 Jan; 31(1):78-83. PubMed ID: 17898020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions.
    Loh CH; Peters SP; Lovings TM; Ohar JA
    Ann Am Thorac Soc; 2017 Aug; 14(8):1305-1311. PubMed ID: 28406710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.